Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

359 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CCR2 and CCR5 co-inhibition modulates immunosuppressive myeloid milieu in glioma and synergizes with anti-PD-1 therapy.
Pant A, Hwa-Lin Bergsneider B, Srivastava S, Kim T, Jain A, Bom S, Shah P, Kannapadi N, Patel K, Choi J, Cho KB, Verma R, Yu-Ju Wu C, Brem H, Tyler B, Pardoll DM, Jackson C, Lim M. Pant A, et al. Among authors: pardoll dm. Oncoimmunology. 2024 Apr 4;13(1):2338965. doi: 10.1080/2162402X.2024.2338965. eCollection 2024. Oncoimmunology. 2024. PMID: 38590799 Free PMC article.
Neurotrophic factor Neuritin modulates T cell electrical and metabolic state for the balance of tolerance and immunity.
Yu H, Nishio H, Barbi J, Mitchell-Flack M, Vignali PDA, Zheng Y, Lebid A, Chang KY, Fu J, Higgins M, Huang CT, Zhang X, Li Z, Blosser L, Tam A, Drake CG, Pardoll DM. Yu H, et al. Among authors: pardoll dm. bioRxiv [Preprint]. 2024 Feb 2:2024.01.31.578284. doi: 10.1101/2024.01.31.578284. bioRxiv. 2024. PMID: 38352414 Free PMC article. Preprint.
Distinct Myeloid Derived Suppressor Cell Populations Promote Tumor Aggression in Glioblastoma.
Jackson C, Cherry C, Bom S, Dykema AG, Thompson E, Zheng M, Ji Z, Hou W, Li R, Zhang H, Choi J, Rodriguez F, Weingart J, Yegnasubramanian S, Lim M, Bettegowda C, Powell J, Eliesseff J, Ji H, Pardoll D. Jackson C, et al. bioRxiv [Preprint]. 2023 Mar 27:2023.03.26.534192. doi: 10.1101/2023.03.26.534192. bioRxiv. 2023. PMID: 37034584 Free PMC article. Preprint.
Cancer therapy with antibodies.
Paul S, Konig MF, Pardoll DM, Bettegowda C, Papadopoulos N, Wright KM, Gabelli SB, Ho M, van Elsas A, Zhou S. Paul S, et al. Among authors: pardoll dm. Nat Rev Cancer. 2024 Jun;24(6):399-426. doi: 10.1038/s41568-024-00690-x. Epub 2024 May 13. Nat Rev Cancer. 2024. PMID: 38740967 Review.
Metabolic reprogramming of tumor-associated macrophages using glutamine antagonist JHU083 drives tumor immunity in myeloid-rich prostate and bladder cancer tumors.
Praharaj M, Shen F, Lee AJ, Zhao L, Nirschl TR, Theodros D, Singh AK, Wang X, Adusei KM, Lombardo KA, Williams RA, Sena LA, Thompson EA, Tam A, Yegnasubramanian S, Pearce EJ, Leone RD, Alt J, Rais R, Slusher BS, Pardoll DM, Powell JD, Zarif JC. Praharaj M, et al. Among authors: pardoll dm. Cancer Immunol Res. 2024 May 3. doi: 10.1158/2326-6066.CIR-23-1105. Online ahead of print. Cancer Immunol Res. 2024. PMID: 38701369
TRBC1-targeting antibody-drug conjugates for the treatment of T cell cancers.
Nichakawade TD, Ge J, Mog BJ, Lee BS, Pearlman AH, Hwang MS, DiNapoli SR, Wyhs N, Marcou N, Glavaris S, Konig MF, Gabelli SB, Watson E, Sterling C, Wagner-Johnston N, Rozati S, Swinnen L, Fuchs E, Pardoll DM, Gabrielson K, Papadopoulos N, Bettegowda C, Kinzler KW, Zhou S, Sur S, Vogelstein B, Paul S. Nichakawade TD, et al. Among authors: pardoll dm. Nature. 2024 Apr;628(8007):416-423. doi: 10.1038/s41586-024-07233-2. Epub 2024 Mar 27. Nature. 2024. PMID: 38538786
Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses.
Kelly RJ, Landon BV, Zaidi AH, Singh D, Canzoniero JV, Balan A, Hales RK, Voong KR, Battafarano RJ, Jobe BA, Yang SC, Broderick S, Ha J, Marrone KA, Pereira G, Rao N, Borole A, Karaindrou K, Belcaid Z, White JR, Ke S, Amjad AI, Weksler B, Shin EJ, Thompson E, Smith KN, Pardoll DM, Hu C, Feliciano JL, Anagnostou V, Lam VK. Kelly RJ, et al. Among authors: pardoll dm. Nat Med. 2024 Apr;30(4):1023-1034. doi: 10.1038/s41591-024-02877-z. Epub 2024 Mar 19. Nat Med. 2024. PMID: 38504015 Free PMC article. Clinical Trial.
Comparing anti-tumor and anti-self immunity in a patient with melanoma receiving immune checkpoint blockade.
Chen S, McMiller TL, Soni A, Succaria F, Sidhom JW, Cappelli LC, Casciola-Rosen LA, Morales IR, Sankaran P, Berger AE, Deutsch JS, Zhu QC, Anders RA, Hooper JE, Pardoll DM, Lipson EJ, Taube JM, Topalian SL. Chen S, et al. Among authors: pardoll dm. J Transl Med. 2024 Mar 5;22(1):241. doi: 10.1186/s12967-024-04973-7. J Transl Med. 2024. PMID: 38443917 Free PMC article.
Circulating cancer-specific CD8 T cell frequency is associated with response to PD-1 blockade in Merkel cell carcinoma.
Pulliam T, Jani S, Jing L, Ryu H, Jojic A, Shasha C, Zhang J, Kulikauskas R, Church C, Garnett-Benson C, Gooley T, Chapuis A, Paulson K, Smith KN, Pardoll DM, Newell EW, Koelle DM, Topalian SL, Nghiem P. Pulliam T, et al. Among authors: pardoll dm. Cell Rep Med. 2024 Feb 20;5(2):101412. doi: 10.1016/j.xcrm.2024.101412. Epub 2024 Feb 10. Cell Rep Med. 2024. PMID: 38340723 Free PMC article.
359 results